Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2018

01-12-2018 | Hepatitis B (J Lim, Section Editor)

Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes

Authors: Rakesh Biswas, Pegah Golabi, Zobair M. Younossi

Published in: Current Hepatology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

Hepatitis B virus (HBV) infects a large number of people worldwide causing tremendous clinical burden related to decompensated cirrhosis and hepatocellular carcinoma (HCC). Although clinical consequences of HBV are well described, the impact of chronic HBV infection on patient-reported outcomes (PROs) is not well described.

Recent Findings

Mostly asymptomatic, some HBV patients do have some impairment of their health-related quality of life. In general, the use of interferon-based regimens for HBV has been associated with negative impact on both physical function and psychological function of the treated patients. In contrast, oral antiviral regimens for HBV have few side effects and do not seem to impair PROs.

Summary

Assessment of PROs for HBV-infected patients is important. These assessments are especially useful in the context of treatment and the clinical trials of future oral antiviral regimens for HBV.
Literature
1.
Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500.CrossRef
2.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRef
3.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–55.CrossRef
4.
Sanyal AJ, Boyer T, Terrault N, Lindor K. Zakim and Boyer’s Hepatology, vol. 2016. Philadelphia, PA: Elsevier; 2018.
5.
Lavanchy D, Hepatitis B. virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.CrossRef
6.
7.
Lai C-L, Yuen M-F. Chronic hepatitis B--new goals, new treatment. N Engl J Med. 2008;359:2488–91.CrossRef
8.
Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11:527–38.
9.
Liaw Y-F. Impact of therapy on the long-term outcome of chronic hepatitis B. Clin Liver Dis. 2013;17:413–23.CrossRef
10.
•• Younossi ZM. Patient-reported outcomes for patients with chronic liver disease. Clin Gastroenterol Hepatol. 2018;16:793–9 The assessment and interpretation of PROs in CLD and why they are important in clinical practice was explored. CrossRef
11.
Evon DM. Incorporating patient-reported outcomes into hepatitis C virus treatment studies. Clin Gastroenterol Hepatol. 2014;12:1360–2.CrossRef
12.
• Younossi ZM, Stepanova M, Reddy R, Manns MP, Bourliere M, Gordon SC, et al. Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. Liver Int [Internet]. 2018; Available from: https://​doi.​org/​10.​1111/​liv.​13900. This study suggests that viral suppression is important for PRO improvement.
13.
Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM. Hepatitis C virus-infected patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. J Infect Dis. 2018;217:1033–43.CrossRef
14.
Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, et al. Hepatitis C in patients with minimal or no hepatic fibrosis: the impact of treatment and sustained virologic response on patient-reported outcomes. Clin Infect Dis. 2018;66:1742–50.
15.
Younossi ZM, Stepanova M, Jacobson IM, Asselah T, Gane EJ, Lawitz E, et al. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther. 2018;47:259–67.
16.
Younossi ZM, Stepanova M, Gordon S, Zeuzem S, Mann MP, Jacobson I, et al. Clin Gastroenterol Hepatol. 2018;16:567–74 e6.
17.
Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017;37:1796–804.CrossRef
18.
Younossi ZM, Stepanova M, Charlton M, Curry MP, O’Leary JG, Brown RS, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122–32.
19.
Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir and Velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017;15:421–30 e6.
20.
Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Henry L, Hunt S. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016;23:857–65.CrossRef
21.
Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016;63:1042–8.
22.
Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111:808–16.CrossRef
23.
Younossi ZM, Stepanova M, Henry L, Younossi I, Weinstein A, Nader F, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat. 2016;23:623–30.
24.
Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65:33–9.
25.
Younossi ZM, Stepanova M, Chan HLY, Lee MH, Yu M-L, Dan YY, et al. Patient-reported Outcomes in asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine. 2016;e2702:95.
26.
Younossi ZM, Stepanova M, Nader F, Henry L. Patient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon- and ribavirin-free Regimens. J Am Geriatr Soc. 2016;64:386–93.CrossRef
27.
Younossi ZM, Stepanova M, Pol S, Bronowicki J-P, Carrieri MP, Bourlière M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016;36:42–8.CrossRef
28.
Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798–808.
29.
Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497–520.CrossRef
30.
Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, et al. Sofosbuvir and Ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C Virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212:367–77.
31.
Younossi ZM, Stepanova M, Zeuzem S, Dusheiko G, Esteban R, Hezode C, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol. 2014;61:228–34.
32.
Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59:2161–9.
33.
•• Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, et al. Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes. Clin Gastroenterol Hepatol [Internet]. 2018; Available from: https://​doi.​org/​10.​1016/​j.​cgh.​2018.​02.​037 Changes in PROs in patients treated for chronic HBV infection were assessed.
34.
Kim JH, Kwon SY, Lee YS, Lee JH, Lee Y-S, Lee CH. Virologic response to therapy increases health-related quality of life for patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:291–6.CrossRef
35.
• Karacaer Z, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, et al. Health Qual Life Outcomes. 2016;14:153 The HRQOL score of CHB patients was worsened when the disease becomes active and use of an antiviral therapy can contribute to increasing HRQOL of patients.
36.
Lam ETP, Lam CLK, Lai CL, Yuen MF, Fong DYT, So TMK. Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes. 2009;7:52.CrossRef
37.
Ong SC, Mak B, Aung MO, Li S-C, Lim S-G. Health-related quality of life in chronic hepatitis B patients. Hepatology. 2008;47:1108–17.CrossRef
38.
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65.CrossRef
39.
Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, et al. Chronic hepatitis B: what should be the goal for new therapies? Antivir Res. 2013;98:27–34.
40.
41.
Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G, et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther. 2009;30:469–76.
42.
Gilson BS, Gilson JS, Bergner M, Bobbit RA, Kressel S, Pollard WE, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65:1304–10.
43.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.
44.
Jay CL, Butt Z, Ladner DP, Skaro AI, Abecassis MM. A review of quality of life instruments used in liver transplantation. J Hepatol. 2009;51:949–59.CrossRef
45.
Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295–300.CrossRef
46.
Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017;37:1209–18.
47.
Younossi ZM, Stepanova M, Henry L. Performance and validation of chronic liver disease questionnaire-hepatitis C version (CLDQ-HCV) in clinical trials of patients with Chronic Hepatitis C. Value Health. 2016;19:544–51.CrossRef
48.
Zhou K-N, Zhang M, Wu Q, Ji Z-H, Zhang X-M, Zhuang G-H. Psychometrics of chronic liver disease questionnaire in Chinese chronic hepatitis B patients. World J Gastroenterol. 2013;19:3494–501.CrossRef
49.
Spiegel BMR, Bolus R, Han S, Tong M, Esrailian E, Talley J, et al. Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. Hepatology. 2007;46:113–21.
50.
Escorpizo R. Understanding work productivity and its application to work-related musculoskeletal disorders. Int J Ind Ergon. 2008;38:291–7.CrossRef
51.
Zhu H-P, Gu Y-R, Zhang G-L, Su Y-J, Wang KE, Zheng Y-B, et al. Depression in patients with chronic hepatitis B and cirrhosis is closely associated with the severity of liver cirrhosis. Exp Ther Med. 2016;12:405–9.
52.
Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, et al. Health related quality of life in people with advanced chronic liver disease. J Hepatol. 2014;61:1158–65.
53.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–52.CrossRef
54.
Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120:170–8.
55.
Fotos NV, Elefsiniotis I, Patelarou A, Giakoumidakis K, Patelarou E, Kouros A, et al. Psychological disorders and quality of life among patients with chronic viral hepatitis: a single-center cross-sectional study with pair-matched healthy controls. Gastroenterol Nurs. 2018;41:206–18.
56.
Zhuang G, Zhang M, Liu Y, Guo Y, Wu Q, Zhou K, et al. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls. Health Qual Life Outcomes. 2014;12:101.
57.
58.
Golabi P, Sayiner M, Bush H, Gerber LH, Younossi ZM. Patient-reported outcomes and fatigue in patients with chronic hepatitis C infection. Clin Liver Dis. 2017;21:565–78.CrossRef
59.
Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14:156–64 e3.CrossRef
60.
Austin PW, Gerber L, Karrar AK. Fatigue in chronic liver disease: exploring the role of the autonomic nervous system. Liver Int. 2015;35:1489–91.CrossRef
61.
Evon DM, Wahed AS, Johnson G, Khalili M, Lisker-Melman M, Fontana RJ, et al. Fatigue in patients with chronic hepatitis B living in North America: results from the Hepatitis B Research Network (HBRN). Dig Dis Sci. 2016;61:1186–96.
62.
Ashrafi M, Modabbernia A, Dalir M, Taslimi S, Karami M, Ostovaneh MR, et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. J Psychosom Res. 2012;73:218–24.
63.
Modabbernia A, Ashrafi M, Malekzadeh R, Poustchi H. A review of psychosocial issues in patients with chronic hepatitis B. Arch Iran Med. 2013;16:114–22.PubMed
Metadata
Title
Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes
Authors
Rakesh Biswas
Pegah Golabi
Zobair M. Younossi
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0434-6

Other articles of this Issue 4/2018

Current Hepatology Reports 4/2018 Go to the issue

Hepatitis B (J Lim, Section Editor)

Long-term Outcomes in Patients with HBV Treated with Antiviral Agents

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls

Hepatitis B (J Lim, Section Editor)

Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B

Correction

Correction: The Role of Anticoagulation in Treating Portal Hypertension

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?

Fatty Liver Disease (Z Younossi, Section Editor)

Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits